Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2871798 | The Annals of Thoracic Surgery | 2015 | 10 Pages |
Abstract
BH-ONCAB is a safe and comparable alternative to C-ONCAB in terms of early mortality and late survival. Furthermore, BH-ONCAB may confer a particular advantage in preventing perioperative myocardial infarction and reducing overall blood loss. Future work should focus on larger matched studies and multicenter randomized controlled trials that risk-stratify patients according to preoperative ventricular function and renal insufficiency to allow us to optimize our surgical revascularization strategy in these high-risk patients.
Related Topics
Health Sciences
Medicine and Dentistry
Cardiology and Cardiovascular Medicine
Authors
Umar A.R. MBBS, Leanne MRCS, PhD, Amir H. MRCS, George MD, John MD, Hutan MRCS, PhD, Thanos FRCS, PhD,